Skip Navigation


JAC Advance Access originally published online on October 28, 2006
Journal of Antimicrobial Chemotherapy 2007 59(1):92-96; doi:10.1093/jac/dkl445
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
59/1/92    most recent
dkl445v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by L'homme, R. F. A.
Right arrow Articles by Burger, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by L'homme, R. F. A.
Right arrow Articles by Burger, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults

Rafaëlla F. A. L'homme1,2,*, Tim Dijkema3, Adilia Warris2,4, Andre J. A. M. van der Ven2,5, Diana M. Gibb6 and David M. Burger1,2

1 Department of Clinical Pharmacy, Radboud University Medical Centre Nijmegen, The Netherlands 2 Nijmegen University Centre for Infectious Diseases (NUCI) Nijmegen, The Netherlands 3 Clinical Research Centre Nijmegen, Radboud University Medical Centre Nijmegen, The Netherlands 4 Department of Paediatrics, Radboud University Medical Centre Nijmegen, The Netherlands 5 Department of General Internal Medicine, Radboud University Medical Centre Nijmegen, The Netherlands 6 Medical Research Council/Clinical Trials Unit London, UK

Received 26 July 2006; returned 4 September 2006; revised 9 October 2006; accepted 9 October 2006

*Correspondence address. Department of Clinical Pharmacy, 864 Radboud University Medical Centre, Geert Grooteplein 10, 6525 GA, Nijmegen, The Netherlands. Tel: +31-24-3616405; Fax: +31-24-3668755; E-mail: R.Lhomme{at}akf.umcn.nl

Objectives: Cipla Pharmaceuticals have developed generic fixed-dose combinations of stavudine, lamivudine and nevirapine for HIV-infected children (Pedimune Baby and Junior). We determined the pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune and compared these with the branded products.

Methods: This Phase I, comparative, single-centre, open-label, three-period, single-dose study was designed as a pilot study to exclude large differences in pharmacokinetics. Six healthy males were randomized to the following regimen sequences: ABC; ACB; BCA; BAC; CAB; CBA (A = reference, B = Pedimune Baby, C = Pedimune Junior). Single doses of medication were administered at 3 time points 4 weeks apart. An 8 h pharmacokinetic curve was recorded at day 1 of every cycle after medication intake. In addition, blood samples were taken on days 2, 3, 4, 8 and 15.

Results: Non-parametric statistical tests revealed no statistically significant differences in Cmax (0.173 ≤ P ≤ 0.753) and Tmax (0.317 ≤ P ≤ 1.000) of stavudine, lamivudine and nevirapine between the two Pedimune formulations and the branded drugs. Also, there were no significant differences in AUC0–{infty} of stavudine, lamivudine and nevirapine between Pedimune Junior and the branded drugs (0.345 ≤ P ≤ 0.600) and between Pedimune Baby and the branded drug for nevirapine (P = 0.463). In contrast, the AUC0–{infty} of stavudine (mean change: +21%; P = 0.046) and lamivudine (mean change: +14%; P = 0.028) differed significantly between Pedimune Baby and the branded drugs, but these changes were considered not clinically significant.

Conclusions: The pharmacokinetic profiles of stavudine, lamivudine and nevirapine in Pedimune Baby and Junior are comparable to the branded products. Based on these results, it is acceptable to test the pharmacokinetics and dosing requirements of Pedimune in HIV-infected children.

Keywords: stavudine , lamivudine , nevirapine


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.